Golden Seeds Closes Second Fund with $26.5M

Golden Seeds, an investment firm focused on women entrepreneurs, has closed its second fund with $26.5 million in committed capital. Golden Seeds Fund 2 LP will invest across technology, life sciences and consumer goods. The fund already has eight portfolio companies, including AboutOne, maker of an online household management system; and Cognition Therapeutics, which is developing drugs for Alzheimer’s disease. Golden Seeds is based in New York.

PRESS RELEASE
Golden Seeds closed its second fund with $26.5 million in committed capital for investments in early stage, high growth companies across at least three sectors, including technology, life sciences and consumer goods. The fund already boasts eight portfolio companies:

AboutOne – online household management system
Cognition Therapeutics – drug discovery for Alzheimer’s disease
Hatsize – cloud-based training and demonstrations of complex technologies
LARK – sleep system that helps you wake better, and sleep better too
Open Road Integrated Media – digital publisher and multimedia content company
RuMe – manufacturer and distributor of fair trade reusable fashion items
Style for Hire – national network of personal stylists trained by celebrity Stacy London
TextureMedia – social media platform connecting the textured hair community

“This capital gives us a critical base to invest and support the excellent companies we are seeing,” said Jo Ann Corkran, Managing Director and Lead Partner of Golden Seeds Fund 2 LP. “We were pleased to find investors across the country who support our investment thesis,” said Lynn Polakoff Baine, Golden Seeds Managing Director, who led the fund-raising effort for the partnership.

Consistent with Golden Seeds’ seven year track record, Fund 2 invests in women entrepreneurs where one woman in the C-Suite with significant equity meets the definition. “Typically, our companies have a woman founder and CEO, but truly it is gender diversity we are investing in,” said Stephanie Hanbury-Brown, Managing Director and Golden Seeds’ Founder. “In some cases, such as Cognition Therapeutics, Dr. Susan Catalano, the Founder and Chief Scientific Officer, has teamed up with a male CEO with significant industry experience,” confirmed Peggy Wallace, Managing Director, who partnered with Hanbury-Brown in the firm’s first fund.

Members of the General Partnership’s investment committee are: Jo Ann Corkran, Jim Estill, Stephanie Hanbury-Brown, Dr. Nada Jain, Kathryn Swintek, Tim O’Neill, Peggy Wallace and Joan Zief.

About Golden Seeds
Golden Seeds is an investment firm dedicated to achieving above market returns for investors through the empowerment of women entrepreneurs. Golden Seeds has four primary operations fulfilling its purpose: An Angel Forum consisting of over 230 men and women investors (the fourth largest in the US), a growing family of Venture Capital funds, an educational Academy, and a Private Equity business.